Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

PURPOSE: To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial (ClinicalTrials.gov identifier:...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, Eric, Huijberts, Sanne, Grothey, Axel, Yaeger, Rona, Cuyle, Pieter-Jan, Elez, Elena, Fakih, Marwan, Montagut, Clara, Peeters, Marc, Yoshino, Takayuki, Wasan, Harpreet, Desai, Jayesh, Ciardiello, Fortunato, Gollerkeri, Ashwin, Christy-Bittel, Janna, Maharry, Kati, Sandor, Victor, Schellens, Jan H.M., Kopetz, Scott, Tabernero, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370699/
https://www.ncbi.nlm.nih.gov/pubmed/30892987
http://dx.doi.org/10.1200/JCO.18.02459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370699/
https://www.ncbi.nlm.nih.gov/pubmed/30892987
http://dx.doi.org/10.1200/JCO.18.02459

Ejemplares similares